Pharmaceutical intermediates
Tramentinib Dimethyl Sulfoxide Intermediates
5 pharmaceutical intermediates for Tramentinib Dimethyl Sulfoxide. Indication: Glioma; Anaplastic thyroid carcinoma; Solid tumor; Non-small cell lung cancer; Melanoma; Thyroid cancer.
About Tramentinib Dimethyl Sulfoxide
- Originator
- Japan Tobacco Inc
- Indication
- Glioma; Anaplastic thyroid carcinoma; Solid tumor; Non-small cell lung cancer; Melanoma; Thyroid cancer
- Approved Date
- 05/29/2013
- DS/DP
- 06/10/2025
Available intermediates
5 intermediates currently listed for Tramentinib Dimethyl Sulfoxide. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 2-Fluoro-4-iodoaniline | 29632-74-4 | / | / |
| 6-Amino-3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-1H-pyrimidine-2,4- dione | 871700-28-6 | / | / |
| 3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-6-(methylamino)pyrimidine - 2,4(1H,3H)-dione | 871700-22-0 | / | / |
| 3-Cyclopropyl-1-(2-fluoro-4-iodophenyl)-5-hydroxy-6,8-dimethyl- 1H,8H-pyrido[2,3-d]pyrimidine-2,4,7-trione | 871700-24-2 | / | / |
| Trametinib DMSO solvate | 1187431-43-1 | / | / |
Building toward Tramentinib Dimethyl Sulfoxide?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →